Latest News

EuroPCR Congress 2024 Reveals its Late-Breaking Clinical Trial Presentations
Written by: EuroPCR 2024, Radcliffe Cardiology
EuroPCR Congress 2024 Reveals its Late-Breaking Clinical Trial Presentations
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at American College of Cardiology Congress
Written by: Radcliffe Cardiology, Greg Guillory, Liam McKnight
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at…
Lerodalcibep, a Novel PCSK9, Achieves LDL Targets in 90% of Patients
Written by: Radcliffe Cardiology, Greg Guillory, Carrie Barclay
Lerodalcibep, a Novel PCSK9, Achieves LDL Targets in 90% of Patients
Full Results Following FDA Approval of AGENT Drug-Coated Balloon
Written by: Radcliffe Cardiology, Jordan Rance; Special Editor: Greg Guillory
Full Results Following FDA Approval of AGENT Drug-Coated Balloon
Semaglutide Produces Positive Kidney and CV Outcomes in the Flow Trial
Written by: Radcliffe Cardiology, Karen Bell; Special Editor: Greg Guillory
Semaglutide Produces Positive Kidney and CV Outcomes in the Flow Trial
Increased Physical Activity Linked to Reduced Heart Failure Risk in Older Women
Written by: Radcliffe Cardiology, Jordan Rance; Special Editor: Greg Guillory
Increased Physical Activity Linked to Reduced Heart Failure Risk in Older Women
Treatment Effect of NOAC Vs Wafarin in AF Shows Generally Consistent Stroke Rates Across the Spectrum of BMI and Body Weight
Written by: Radcliffe Cardiology, Carrie Barclay; Special Editor: Greg Guillory
Treatment Effect of NOAC Vs Wafarin in AF Shows Generally Consistent Stroke Rates Across the Spectrum of BMI…
European Heart Rhythm Association (EHRA) Congress 2024 Reveals its Late-Breaking Clinical Trial Presentations for 2024
Written by: EHRA 2024
European Heart Rhythm Association (EHRA) Congress 2024 Reveals its Late-Breaking Clinical Trial…
Technology and Heart Failure Therapeutics (THT) Conference Unveils its Late-Breaking Clinical Trial Presentations for 2024
Written by: THT 2024
Technology and Heart Failure Therapeutics (THT) Conference Unveils its Late-Breaking Clinical Trial…
New Data: 70% of Americans Unaware of Common Vascular Disease That is One of the Leading Causes of Amputation
Written by: PAD Pulse Alliance
New Data: 70% of Americans Unaware of Common Vascular Disease That is One of the Leading Causes of…

External news

Written by: Medscape
Pre-op Evaluations: Does This Patient Really Need One?
Written by: Medscape
Private Equity: Medicine’s Professional Groups Must Weigh In
Written by: Medscape
Mitral Regurgitation in HF: Optimizing Outcomes
Written by: Cardiac Vascular News
At RSNA 2024, Agfa Radiology Solutions’ in-booth presentations empower X-ray experts with insights and innovations
Written by: Cardiac Vascular News
RADPAIR Named “Best New Radiology Vendor 2024” at AuntMinnie.com’s Minnies Awards
Written by: Cardiac Vascular News
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
Written by: Cardiac Vascular News
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Written by: Medscape
First TAVR for Aortic Regurgitation Moves to Phase 3 Trial
Written by: Medscape
Thrombectomy Tops Thrombolysis in Pulmonary Embolism Trial
Written by: Cardiac Vascular News
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results